Clinical trials: Alzheimer's Type Dementia
Alzheimer's Disease
Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease
This study evaluated the effect of 6 or 12 infusions of different doses of octagam (intravenous immunoglobulin [IVIG]) 10% on the reduction of amyloid beta peptide (Aβ) in cerebral spinal fluid (CSF) and on the increase of Aβ in…
- Trial name
- NCT00812565
- Testing
- octagam 10%
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Octapharma
Alzheimer or Mild Cognitive Impairment
ARIADE : Augmented Reality for Improving Autonomy in Dementia
Navigating according to a specific goal is a common activity of everyday life. Spatial navigation requires the implementation of motor and perceptual functions (sight, walking, proprioception), but also various cognitive…
- Trial name
- ARIADE (NCT04742465)
- Testing
- Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Rennes University Hospital
Alzheimer Dementia, Alzheimer's Disease
Association of Cognition With Functional Mobility in People With Alzheimer's Disease
This study aimed to investigate relationship between cognitive function and functional mobility in Alzheimer's disease.
- Conditions
- Alzheimer Dementia, Alzheimer's Disease, Dementia, Alzheimer Type
- Trial name
- NCT05113732
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Istanbul University - Cerrahpasa
Alzheimer's Disease
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
This was a multicenter, prospective, phase IV study evaluating safety, tolerability and effectiveness of rivastigmine 27 mg -15 cm^2 transdermal patch prescribed in patients with severe dementia of the Alzheimer's type as per…
- Trial name
- NCT02989402
- Testing
- Rivastigmine
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease
Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers
The purpose of this study is to determine whether a comprehensive cognitive-behavioral therapy-based, multi-component treatment programme is effective in the treatment of neuropsychiatric symptoms of patients with mild…
- Trial name
- CBTAC (NCT01273272)
- Testing
- Comprehensive, CBT-based, multi-component treatment, Treatment as usual
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
Alzheimer Disease, Dementia of Alzheimer Type
Assess Fibrin in Brains With AD/ADRD
The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.
- Trial name
- NCT05336695
- Testing
- PET/MR Imaging, 64Cu-FBP8
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Alzheimer's Disease, Dementia
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia
The objective of the study is to define the performance of blood-based signatures for Alzheimer's Disease (AD) in different patients populations including AD, non-AD dementia, and non-demented controls.
- Trial name
- NCT00880347
- Testing
- Blood sampling
- Where
- 21 sites in France
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Exonhit
Alzheimer's Type Dementia
A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with severe Alzheimer's disease.
- Trial name
- NCT01276353
- Testing
- E2020
- Where
- 11 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eisai Inc.
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT04623242)
- Testing
- Gantenerumab, Solanezumab
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT06424236)
- Testing
- Gantenerumab
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease
Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease
The main objective of this study is to evaluate the effect of 3 months of "Snoezelen-type" multi-sensory care sessions on NeuroPsychiatric Inventory Questionnaire (NPI-Q) scores for patients with Alzheimer's-type…
- Trial name
- SensiCare (NCT01819714)
- Testing
- Multi-sensory supportive care
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Agitation, Alzheimer's Type Dementia
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
- Trial name
- NCT05397639
- Testing
- Masupirdine 50 mg, Masupirdine 100 mg
- Where
- 44 sites in United States, Croatia and 2 more
- Volunteers
- 375 people
- Sponsor
- Suven Life Sciences Limited
Dementia Alzheimer Type
Pain Perception in Alzheimer's Disease
The purpose of this study is to determine response to pain in Alzheimer's disease.We plan to study the effect of diffuse noxious inhibitory controls(counterirritation phenomenon)and the autonomic nervous system reaction(reflected…
- Trial name
- NCT00192816
- Testing
- reaction to pain
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Alzheimer's Disease
CPC-201 Alzheimer's Disease Type Dementia: PET Study
The purpose of this study is to compare the effect of low and high dose CPC-201 on brain function including cerebral acetylcholinesterase (AChE) activity measured by positron emission tomography (PET).
- Trial name
- NCT02860065
- Testing
- CPC-201, Positron emission tomography (PET)
- Where
- United States
- Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Dementia, Alzheimer's Disease
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
- Trial name
- NCT00104273
- Testing
- Rasagiline
- Where
- 58 sites in United States, Australia and 2 more
- Volunteers
- 376 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Alzheimer Disease, Dementia of Alzheimer Type
A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease
This study is designed to evaluate treatment effects of ATH-1017 (fosgonimeton) in mild to moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.
- Trial name
- ACT-AD (NCT04491006)
- Testing
- ATH-1017
- Where
- 13 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- LeonaBio
Alzheimer Disease, Alzheimer Disease 1
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)
This is a randomized, double-blind, sham-controlled pivotal study of sensory stimulation in subjects with mild to moderate AD. Up to approximately 670 subjects will be treated with either Active or Sham investigational device…
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- HOPE (NCT05637801)
- Testing
- Spectris™ AD - Active
- Where
- 68 sites in United States
- Volunteers
- 673 people
- Sponsor
- Cognito Therapeutics, Inc.
Agitation in Patients With Dementia of the Alzheimer's Type
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This was an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305.
- Trial name
- NCT02446132
- Testing
- AVP-786
- Where
- 227 sites in United States, Bulgaria and 8 more
- Volunteers
- 1,197 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimers Disease, Dementia
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU-002 (NCT06647498)
- Testing
- Remternetug
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Dementia
Movement Intervention for Memory Enhancement
Dancing is a complex sensorimotor rhythmic activity that integrates cognitive, physical, and social components and is applicable to seniors with various fitness levels.
- Conditions
- Alzheimer Disease, Dementia, Cognitive Decline, Cognitive Impairment
- Trial name
- MIME (NCT03475316)
- Testing
- Social Dancing, Treadmill Walking
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine